Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Trial Details

NCT ID

NCT06366789

Phase

PHASE1

Sponsor

Lomond Therapeutics Holdings, Inc.

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• ZE46-0134

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• San Francisco, California, United States|37.77493,-122.41942
• Atlanta, Georgia, United States|33.749,-84.38798
• Chicago, Illinois, United States|41.85003,-87.65005
• Lawrence, Kansas, United States|38.97167,-95.23525

Key Eligibility Criteria

• Written Informed Consent must be obtained from the patient or legally authorized representative prior to any study-related procedures (including wi…
• Patient is ≥18 years of age at the time of obtaining informed consent.
• Patient is refractory to or relapsed after first-line AML therapy (with or without HSCT).
• Group 1: Patient must have a confirmed FLT3-ITD or FLT3-TKD mutation by central laboratory testing. Group 2: Patient must have a documented SF3B1, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.